Trial Profile

Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 23 Feb 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Oprozomib (Primary)
Indications Haematological malignancies; Multiple myeloma; Waldenstrom's macroglobulinaemia
Focus Adverse reactions; Therapeutic Use
Sponsors Amgen; Onyx Pharmaceuticals

Most Recent Events

17 Feb 2021 Status changed from completed to discontinued. Reason the study was stopped: A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in 2011-001 was halted.
13 Aug 2019 Status changed from active, no longer recruiting to completed.
31 Jul 2019 Planned End Date changed from 29 Jul 2019 to 12 Aug 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com